New drug cocktail shows promise in shrinking advanced melanoma before surgery
NCT ID NCT03554083
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tested a combination of targeted drugs (vemurafenib and cobimetinib) and immunotherapy (atezolizumab and tiragolumab) given before surgery to 64 patients with high-risk stage III melanoma. The goal was to see if the treatment could eliminate or shrink the cancer enough to improve outcomes. The study measured how many patients had no cancer left at surgery and how long they stayed cancer-free afterward.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Vemurafenib, cobimetinib, atezolizumab, and tiragolumab
- What this could lead to
- If successful, this could point toward a more effective way to shrink high-risk stage III melanoma before surgery, potentially reducing the chance of the cancer coming back.
- What could go wrong
- This is a small, early-phase pilot trial with only 64 participants, so results may not apply to everyone. The combination of drugs can cause significant side effects, and it's not yet clear if it improves long-term survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
-
University of Minnesota/Masonic Cancer Center
Minneapolis, Minnesota, 55455, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat cancers
- Two-Drug combo targets Hard-to-Treat melanoma
- Wheat germ supplement studied for immune boost in advanced cancer
- Can morning light boost melanoma treatment? new trial tests simple iPad therapy
- Can a smaller dose of this cancer drug still work? new trial aims to find out
- New drug combo shows promise in early trial for advanced melanoma